NGM Biopharmaceuticals, Inc. Common Stock

NGM

Market cap $129M

LOS ANGELES, CA / ACCESSWIRE / March 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

LOS ANGELES, CA / ACCESSWIRE / March 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP. Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders.

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024--